PeptideStack
5.2kquestions
20kanswers
220users

Is a 98.4% result from PeptideMeter comparable to 97.1% from PeptideMeter?

Asked 11 Jul 2024Modified 22 months agoViewed 22k times
24

The particulars: 98.4% · PeptideMeter · 97.1% · PeptideMeter.

The comparison I want does not seem to exist anywhere in a form I can evaluate.

I have read the arguments for each and they do not engage with each other.

So which one, and on what grounds?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

788 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
reference-standard
reference-standard

Certified reference materials and in-house standards: traceability, the certificate of the standard itself, system suitability, and why every…

179 questions
shareeditfollowflag
OB
askedolu_babatunde14k1711 Jul 2024
Is there a reason to prefer the second method over the first, other than cost? – tandem_gradient 2 months ago
add a comment

5 Answers

Accepted answer first, then by votes
89

Accepted answer

Read the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

Mass shifts and what they usually mean

Δ mass (Da)Most likely causeDistinguishing feature
+1Deamidation (Asn or Gln)New peak, slightly earlier retention
−17Loss of ammoniaOften with deamidation
−18Dehydration / succinimidepH-dependent, reversible
+16Oxidation (Met, Trp)Earlier retention, light-related
−128Missing Gln or LysDeletion sequence from synthesis
0Isomer: racemisation or scramblingSame mass, shifted retention

On the detail: detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
RC
answered · acceptedRP_C1885k15822 Aug 2024
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
36

The part that matters: the honest answer is that the achievable range of plausible purity figures for a given vial is wider than most people expect.

Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.

The underlying point is that the fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

Compare purity within a single laboratory on the same method, never across laboratories.

edited 2 Sept 2024 by fib4_reader — added the method parameters

shareimprove this answerflag
FR
answeredfib4_reader35k3811 Aug 2024
24

Worth being precise here: gradient slope is the most powerful parameter and almost nobody mentions it, which is why two reports on the same material disagree by a point.

Gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.

In practice, retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
DR
answeredDr_Priya_Raghunathan94k24831 Jul 2024
20

Stated carefully, understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
AL
answereda_lindgren46k13819 Jul 2024
6Confirming from the other direction: I did the wrong thing and got exactly the predicted outcome. – tyndall_haze 5 months ago
5Is there a reason to prefer the second method over the first, other than cost? – h_pergande 3 months ago
add a comment
15

It helps to be literal here: purity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.

Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
NN
answerednine_point_nine45k1385 Oct 2024

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.